Anthem Biosciences (ANTHEM) investor relations material

Executive summary

• FY26 saw record consolidated revenue of INR 22,801.16 million, up 18% year-over-year, with Q4 being the highest revenue quarter ever and strong growth in both EBITDA and PAT.

• CRDMO business contributed 83% of revenue, Specialty Ingredients 17%, with CRDMO leading growth.

• Audited standalone and consolidated results were approved, with an unmodified audit opinion; a final dividend of INR 2.00 per share was proposed.

• IPO completed and listed on NSE and BSE in July 2025; 20th AGM scheduled for July 22, 2026.

• Maintained a robust net cash position and healthy financials at year-end.

Financial highlights

• Consolidated revenue for FY26 was INR 22,801.16 million, up from INR 19,302.85 million in FY25; Q4 revenue was INR 6,109 million, up 26% year-over-year.

• EBITDA for FY26 was INR 9,896 million (43.4% margin), up 31% year-over-year; Q4 EBITDA was INR 3,184 million (48.1% margin), up 52% year-over-year.

• PAT for FY26 was INR 5,918 million (26% margin), up 31% year-over-year; Q4 PAT was INR 1,898 million (28.7% margin), up 130% year-over-year.

• Net cash position as of March 31, 2026, was INR 13,743 million.

• Other income for the year was INR 156 crore, including forex gains and export incentives.

Outlook and guidance

• Management targets maintaining 20%+ growth in revenue, EBITDA, and PAT, with a focus on CRDMO and Specialty Ingredients.

• Destocking impact is largely behind, with positive restocking trends expected.

• GLP-1 segment and Specialty Ingredients expected to be significant contributors, pending regulatory approvals.

• Continued investment in capacity expansion and advanced manufacturing technologies.

• Focus on building an agile, science-led, future-ready CRDMO platform and sustainable growth.